News

People with myasthenia gravis (MG) face a mean annual healthcare cost of nearly $16,000, according to a survey of MG patients and their caregivers. Medications and treatments accounted for most out-of-pocket expenses (27%), followed by insurance premiums (20%), diagnosis (15%), and caregiving assistance (14%). “Disseminating the findings of this…

People newly diagnosed with myasthenia gravis (MG) in England experience a high disease burden, with about two-thirds having at least one exacerbation, or an episode of disease worsening, and approximately half having one MG-related hospitalization. That’s according to a new study led by researchers from the pharmaceutical company…

Enspryng (satralizumab), tested by Chugai Pharmaceutical as a treatment for generalized myasthenia gravis (gMG), eased disease symptoms and made daily life easier when used in addition to standard of care therapy over six months, but its clinical benefit was somewhat limited. These data from LUMINESCE (NCT04963270), a…

People with myasthenia gravis (MG) have a higher risk of developing cancer in organs other than the thymus, particularly in the skin and gastrointestinal tract, than people without the disease, according to a study. The incidence of such cancers tended to be higher in the five years before and…

Most people with very late-onset myasthenia gravis (MG) — patients in whom symptoms start to manifest at age 65 or older — who are positive for self-reactive antibodies against acetylcholine receptors, or AChRs, show significant clinical improvements within two years of disease onset, according to a new study…

Cartesian Therapeutics has aligned with the U.S. Food and Drug Administration (FDA) on the design of the planned Phase 3 AURORA trial that will test its investigational cell therapy Descartes-08 in people with myasthenia gravis (MG). The FDA, under its special protocol assessment process, provided written agreement…

Nipocalimab outperformed a placebo at easing the severity of generalized myasthenia gravis (gMG) in a Phase 3 clinical trial called Vivacity-MG3. Full results from the trial were detailed in the study, “Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3,…

People who are genetically predisposed to myasthenia gravis (MG) are more likely to develop Graves’ disease and Hashimoto’s thyroiditis, two autoimmune diseases of the thyroid gland, according to a study in China. Researchers also found a genetic link in the opposite direction, where being genetically predisposed to Graves’ disease…

Being younger, having more symptom-free periods, and a delayed positive antibody test were identified as risk factors for a delayed diagnosis of myasthenia gravis (MG) in a study conducted in Denmark. While the study’s findings noted a trend toward shorter diagnosis times in more recent years, the researchers noted…

Treatment with ARGX-119, an experimental therapy being developed by Argenx, led to improvements in muscle strength and survival in a mouse model of myasthenia gravis (MG) driven by self-reactive antibodies that target the muscle-specific kinase (MuSK) protein, a study shows. While the findings indicated ARGX-119 may ease…